DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025.
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
5 May 2025 (4 Days) Date | | - Cons. EPS | - EPS |
10 Mar 2025 Date | | 0.09 Cons. EPS | 0.15 EPS |
5 Nov 2024 Date | | 0.03 Cons. EPS | 0.06 EPS |
6 Aug 2024 Date | | 0.07 Cons. EPS | 0.19 EPS |
7 May 2024 Date | | - Cons. EPS | 0.07 EPS |
5 May 2025 (4 Days) Date | | - Cons. EPS | - EPS |
10 Mar 2025 Date | | 0.09 Cons. EPS | 0.15 EPS |
5 Nov 2024 Date | | 0.03 Cons. EPS | 0.06 EPS |
6 Aug 2024 Date | | 0.07 Cons. EPS | 0.19 EPS |
7 May 2024 Date | | - Cons. EPS | 0.07 EPS |
Medical Devices Industry | Healthcare Sector | Mr. Robert E. Claypoole CEO | CXA Exchange | US09075A1088 ISIN |
United States Country | 1,030 Employees | - Last Dividend | - Last Split | - IPO Date |
Bioventus Inc. is a pioneering medical device company that places a strong emphasis on innovating and providing treatments aimed at enhancing the body's intrinsic healing mechanisms. Operating both in the United States and internationally, the company has carved a niche for itself in the medical device industry by offering a wide range of products designed for pain management, surgical solutions, and restorative therapies. With its foundation in 2011 and headquarters in Durham, North Carolina, Bioventus stands as a beacon of advancement in leveraging medical technology to improve patient outcomes.
Pain Treatments: Bioventus' portfolio addresses non-surgical pain through injection therapies and peripheral nerve stimulation products. Key offerings include:
Surgical Solutions: The company provides surgeons with innovative tools and biomaterials for bone and soft tissue procedures, featuring:
Restorative Therapies: Bioventus also addresses neurologic and musculoskeletal recovery, offering devices that aid in rehabilitation from strokes, multiple sclerosis, or central nervous system disorders. Products include:
The company is also developing the Talisman Pulse Generator and Receiver, a potential breakthrough for peripheral nerve stimulation, showcasing Bioventus' commitment to ongoing innovation and improvement in the field of medical devices.